^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FGFR1 amplification

    i
    Other names: FGFR1, BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM, Fibroblast growth factor receptor 1
    Entrez ID:
    2260
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    #SABCS21 #FOENIXMBC2 #Futibatinib ➕ #fulvestrant in #MBC w/ high-level #FGFR1 amplification 🧬 🔹no DLT in safety lead-in 🔹recommended dose of 20 mg futibatinib combined with fulvestrant 🔹phase 2 expansion study ongoing #SenthilDamodaran #NickTurner @OncoAlert #bcsm @aftimosp (@kevinpunie)
    Clinical • P2 data
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 amplification
    |
    Lytgobi (futibatinib)
    over2years
    Any ongoing clinical trials recruiting patients with colorectal cancer KRAS G12C mutations or FGFR1 amplifications? @weoncologists @BenWestphalen @tmprowell @PTarantinoMD @VivekSubbiah (@bin_abeid)
    Clinical
    |
    KRAS (KRAS proto-oncogene GTPase) • FGFR1 (Fibroblast growth factor receptor 1)
    |
    KRAS mutation • KRAS G12C • FGFR1 amplification • FGFR1 mutation • KRAS G12
    almost4years
    Certainly need to be explore! Clinical trials design for SCLC must be updated. Several case reports are giving insights of #PrecisionMedicine in SCLC like our experience Remarkable Activity Pazopanib in Refractory FGFR1-Amplified ED-SCLC https://t.co/VLY8Hlm2Ov @isliquidbiopsy https://t.co/3Q3ZJIirjW (@ChristianRolfo)
    Clinical
    |
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 amplification
    |
    Votrient (pazopanib)
    4years
    Is There Room for Personalized Medicine in Small-Cell Lung Cancer (SCLC)? Remarkable Activity of Pazopanib in Refractory FGFR1-Amplified ED-SCLC https://t.co/hrfIYJdNxy (@AndresFCardonaZ)
    FGFR1 (Fibroblast growth factor receptor 1)
    |
    FGFR1 amplification
    |
    Votrient (pazopanib)